Psychiatry Core Practice Exam

Lisdexamphetamine, sold under the brand name Vyvanse, is distinguished for its smooth delivery system, primarily due to its unique formulation as a prodrug. When taken, it is converted in the body into its active form, dextroamphetamine, which leads to a gradual increase in stimulant effects. This results in a lower potential for abuse, as the effects do not come on as quickly or intensely as other stimulants, making it more suitable for patients who might be sensitive to the effects of rapid-release stimulants.

In addition to its application in treating attention-deficit/hyperactivity disorder (ADHD), Lisdexamphetamine has been approved for the treatment of moderate to severe binge eating disorder. It helps mitigate the episodes of binge eating by affecting neurotransmitters in the brain, thereby reducing cravings and the urge to binge. This dual utility as both an ADHD treatment and a management option for binge eating disorder underscores its versatility and effectiveness in clinical settings.

Other options presented do not have the same profile regarding smooth delivery and specific use in binge eating disorder. Methylphenidate, while also used for ADHD, operates differently and lacks the specific indication for binge eating disorder. Atomoxetine is a non-stimulant used primarily for ADHD treatment